Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495498 | 0.86 | GABRA5 (0.52) | HPGDSGABRA5MAP4K4 | |
| SCHEMBL16495495 | 0.86 | GABRA5 (0.52) | HPGDSGABRA5MAP4K4 | |
| SCHEMBL16496132 | 0.81 | HPGDS (0.51) | HPGDSTRPV1MAPTTHRBGABRA5 | |
| SCHEMBL16495681 | 0.79 | HPGDS (0.50) | HPGDSTRPV1MAPTTHRBHTR2C | |
| SCHEMBL1542860 | 0.78 | GABRA5 (0.59) | HPGDSGABRA5MAP4K4 | |
| SCHEMBL16495497 | 0.77 | HPGDS (0.55) | HPGDS | |
| SCHEMBL16495786 | 0.77 | HPGDS (0.55) | HPGDSTRPV1MAPTWNT3ASNCA | |
| SCHEMBL13572932 | 0.76 | HPGDS (0.60) | HPGDSTRPV1MAPTGABRA5HTR2C | |
| SCHEMBL16495815 | 0.76 | HPGDS (0.60) | HPGDSTRPV1MAPTGABRA5WNT3A | |
| SCHEMBL16495432 | 0.76 | HPGDS (0.54) | HPGDSTRPV1MAPTTHRBHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885TRPV1 116/4885MAPT 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.